Mast Therapeutics Provides Update On Strategic Direction
- Preliminary Indications of Interest in Reverse Merger Transactions. The Company has received several written indications of interest from privately-held companies, including companies with synergistic clinical-stage drug candidates, and is actively evaluating these opportunities.
- Other Strategic Opportunities. Concurrently, the Company will continue to explore ways to strategically monetize its vepoloxamer assets, including through licensing transactions.
Continued Clinical Developmentof AIR001. In parallel with exploring strategic opportunities, the Company will continue to support ongoing and planned investigator-sponsored clinical studies of its lead asset, AIR001, for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
"Our recently-announced strategic process has generated a number of opportunities that would be transformative for Mast," stated
Forward Looking Statements
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mast-therapeutics-provides-update-on-strategic-direction-300366405.html
Mast Therapeutics, Ioana C. Hone (email@example.com), 858-552-0866 Ext. 303